Pattern of use and efficacy of daratumumab-based therapy in patients with relapsed/refractory light chain amyloidosis in a real-world setting: a single institution experience-Reference-Cited by-同舟云学术

Pattern of use and efficacy of daratumumab-based therapy in patients with relapsed/refractory light chain amyloidosis in a real-world setting: a single institution experience

Published:2022-01-02 Issue:5 Volume:63 Page:1246-1250
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Dima Danai¹^ORCID,Hu Xiao²^ORCID,Dower Joshua²,Zhang Diana³,Comenzo Raymond⁴,Varga Cindy⁴

Affiliation:

1. Hematology/Oncology Division, Cleveland Clinic Foundation, Cleveland, OH, USA

2. Hematology/Oncology Division, Tufts Medical Center, Boston, MA, USA

3. Internal Medicine Division, Massachusetts General Hospital, Boston, MA, USA

4. The John C Davis Myeloma and Amyloid Program in the Division of Hematology-Oncology, Tufts Medical Center, Boston, MA, USA

Funder

Janssen

Caelum

Alnylam

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2021.2018585

Reference19 articles.

1. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis

Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy

3. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA

4. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis

5. AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcomes of venetoclax-based therapy in patients with t(11;14) light chain amyloidosis after failure of daratumumab-based therapy;Amyloid;2024-07-02

2. Response rates to second‐line treatment with daratumumab bortezomib dexamethasone (DVD) in relapsed/refractory light chain amyloidosis (AL) after initial Bortezomib‐based regime;British Journal of Haematology;2024-06-05

3. Daratumumab;Reactions Weekly;2022-07